Apathy is associated with increased amyloid burden in mild cognitive impairment

Journal of Neuropsychiatry and Clinical Neurosciences

Volumn 25, Issue 4, 2013, Pages 302-307

  Marshall, Gad A ^a,b   Donovan, Nancy J ^c   Lorius, Natacha ^a,b   Gidicsin, Christopher M ^c   Maye, Jacqueline ^c   Pepin, Lesley C ^c   Becker, J Alex ^c   Amariglio, Rebecca E ^a,b   Rentz, Dorene M ^a,b   Sperling, Reisa A ^a,b   Johnson, Keith A ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c Dept of Psychiatry Brigham and Women's Hospital Harvard Medical School ^*

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID PROTEIN; FLUORODEOXYGLUCOSE F 18; PITTSBURGH COMPOUND B;

ADULT; AGED; ANTERIOR CINGULATE; APATHY; APATHY EVALUATION SCALE; ARTICLE; BRAIN METABOLISM; CEREBELLUM CORTEX; CLINICAL ARTICLE; DAILY LIFE ACTIVITY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; GERIATRIC DEPRESSION SCALE; HEAD MOVEMENT; HUMAN; LEARNING; MALE; MEMORY DISORDER; MILD COGNITIVE IMPAIRMENT; NEUROIMAGING; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RATING SCALE; SCORING SYSTEM; WECHSLER MEMORY SCALE;

AGED; AGED, 80 AND OVER; AMYLOID; ANILINE COMPOUNDS; APATHY; CEREBRAL CORTEX; FEMALE; FLUORODEOXYGLUCOSE F18; FUNCTIONAL NEUROIMAGING; HUMANS; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; THIAZOLES;

EID: 84899910654     PISSN: 08950172     EISSN: 15457222     Source Type: Journal    
DOI: 10.1176/appi.neuropsych.12060156     Document Type: Article

References (40)

1. Apostolova LG, Cummings JL: Neuropsychiatric manifestations in mild cognitive impairment: a systematic review of the literature. Dement Geriatr Cogn Disord 2008; 25:115-126
2. Mega MS, Cummings JL, Fiorello T, et al: The spectrum of behavioral changes in Alzheimer's disease. Neurology 1996; 46:130-135
3. Peters ME, Rosenberg PB, Steinberg M, et al; Cache County Investigators: prevalence of neuropsychiatric symptoms in CIND and its subtypes: the Cache County Study. Am J Geriatr Psychiatry 2012; 20:416-424
4. Boyle PA, Malloy PF, Salloway S, et al: Executive dysfunction and apathy predict functional impairment in Alzheimer disease. Am J Geriatr Psychiatry 2003; 11:214-221
5. Marshall GA, Rentz DM, Frey MT, et al; Alzheimer's Disease Neuroimaging Initiative: executive function and instrumental activities of daily living in mild cognitive impairment and Alzheimer's disease. Alzheimers Dement 2011; 7:300-308
6. McPherson S, Fairbanks L, Tiken S, et al: Apathy and executive function in Alzheimer's disease. J Int Neuropsychol Soc 2002; 8:373-381
7. Palmer K, Di Iulio F, Varsi AE, et al: Neuropsychiatric predictors of progression from amnestic mild cognitive impairment to Alzheimer's disease: the role of depression and apathy. J Alzheimers Dis 2010; 20:175-183
8. Robert PH, Berr C, Volteau M, et al; PréAL study: apathy in patients with mild cognitive impairment and the risk of developing dementia of Alzheimer's disease: a one-year followup study. Clin Neurol Neurosurg 2006; 108:733-736
9. Cummings JL: Frontal-subcortical circuits and human behavior. Arch Neurol 1993; 50:873-880
10. Mega MS, Cummings JL, Salloway S, et al: The limbic system: an anatomic, phylogenetic, and clinical perspective. J Neuropsychiatry Clin Neurosci 1997; 9:315-330
11. Benoit M, Clairet S, Koulibaly PM, et al: Brain perfusion correlates of the apathy inventory dimensions of Alzheimer's disease. Int J Geriatr Psychiatry 2004; 19:864-869
12. Marshall GA, Monserratt L, Harwood D, et al: Positron emission tomography metabolic correlates of apathy in Alzheimer disease. Arch Neurol 2007; 64:1015-1020
13. Marshall GA, Fairbanks LA, Tekin S, et al: Neuropathologic correlates of apathy in Alzheimer's disease. Dement Geriatr Cogn Disord 2006; 21:144-147
14. Skogseth R, Mulugeta E, Jones E, et al: Neuropsychiatric correlates of cerebrospinal fluid biomarkers in Alzheimer's disease. Dement Geriatr Cogn Disord 2008; 25:559-563
15. Klunk WE, Engler H, Nordberg A, et al: Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004; 55:306-319
16. Rowe CC, Ng S, Ackermann U, et al: Imaging beta-amyloid burden in aging and dementia. Neurology 2007; 68:1718-1725
17. Sperling RA, Laviolette PS, O'Keefe K, et al: Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron 2009; 63:178-188
18. Wolk DA, Price JC, Saxton JA, et al: Amyloid imaging in mild cognitive impairment subtypes. Ann Neurol 2009; 65:557-568
19. Jack CR Jr, Lowe VJ, Senjem ML, et al: 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 2008; 131:665-680
20. Bennett DA, Schneider JA, Bienias JL, et al: Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions. Neurology 2005; 64:834-841
21. Petersen RC, Parisi JE, Dickson DW, et al: Neuropathologic features of amnestic mild cognitive impairment. Arch Neurol 2006; 63:665-672
22. Rosen WG, Terry RD, Fuld PA, et al: Pathological verification of ischemic score in differentiation of dementias. Ann Neurol 1980; 7:486-488
23. Yesavage JA, Brink TL, Rose TL, et al: Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res 1982-1983; 17:37-49
24. Petersen RC: Mild cognitive impairment as a diagnostic entity. J Intern Med 2004; 256:183-194
25. Folstein MF, Folstein SE, McHugh PR: "Mini-Mental State:" a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12:189-198
26. Morris JC: The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993; 43:2412-2414
27. Marin RS, Biedrzycki RC, Firinciogullari S: Reliability and validity of the Apathy Evaluation Scale. Psychiatry Res 1991; 38:143-162
28. Cummings JL: The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology 1997; 48 (Suppl 6):S10-S16
29. Cummings JL, Mega M, Gray K, et al: The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44:2308-2314
30. Mathis CA, Wang Y, Holt DP, et al: Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem 2003; 46:2740-2754
31. Johnson KA, Gregas M, Becker JA, et al: Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol 2007; 62:229-234
32. Gomperts SN, Rentz DM, Moran E, et al: Imaging amyloid deposition in Lewy body diseases. Neurology 2008; 71:903-910
33. Marshall GA, Olson LE, Frey MT, et al: Instrumental activities of daily living impairment is associated with increased amyloid burden. Dement Geriatr Cogn Disord 2011; 31:443-450
34. Becker JA, Hedden T, Carmasin J, et al: Amyloid-b associated cortical thinning in clinically normal elderly. Ann Neurol 2011; 69:1032-1042
35. Price JC, Klunk WE, Lopresti BJ, et al: Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab 2005; 25:1528-1547
36. Rentz DM, Locascio JJ, Becker JA, et al: Cognition, reserve, and amyloid deposition in normal aging. Ann Neurol 2010; 67:353-364
37. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, et al: Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI singlesubject brain. Neuroimage 2002; 15:273-289
38. Landau SM, Harvey D, Madison CM, et al; Alzheimer's Disease Neuroimaging Initiative: Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging 2011; 32:1207-1218
39. Rey A: L'examen clinique en psychologie. Paris, France, Presses Universitaires de France, 1964
40. Albert MS, DeKosky ST, Dickson D, et al: The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7:270-279